Information Provided By:
Fly News Breaks for January 17, 2020
BGNE
Jan 17, 2020 | 08:54 EDT
Morgan Stanley analyst Matthew Harrison resumed coverage of BeiGene (BGNE) with an Overweight rating and $210 price target. The company's recent deal with Amgen (AMGN) offers downside protection while multiple pivotal readouts in 2020, including in first-line CLL and in lung cancer, offer significant upside potential, Harrison tells investors.